## Benjamin Berkman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6749099/publications.pdf

Version: 2024-02-01

47 papers

1,606 citations

16 h-index 315719 38 g-index

47 all docs

47 docs citations

47 times ranked

2394 citing authors

#	Article	IF	CITATIONS
1	Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents. American Journal of Human Genetics, 2015, 97, 6-21.	6.2	453
2	Return of Genomic Results to Research Participants: The Floor, the Ceiling, and the Choices In Between. American Journal of Human Genetics, 2014, 94, 818-826.	6.2	342
3	Genomics really gets personal: How exome and whole genome sequencing challenge the ethical framework of human genetics research. American Journal of Medical Genetics, Part A, 2011, 155, 2916-2924.	1.2	119
4	Do Researchers Have an Obligation to Actively Look for Genetic Incidental Findings?. American Journal of Bioethics, 2013, 13, 32-42.	0.9	81
5	Disclosure of Incidental Findings From Next-Generation Sequencing in Pediatric Genomic Research. Pediatrics, 2013, 131, 564-571.	2.1	76
6	Prenatal Whole Genome Sequencing. Hastings Center Report, 2012, 42, 28-40.	1.0	57
7	Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials. Neurology, 2015, 84, 1488-1494.	1.1	49
8	The unintended implications of blurring the line between research and clinical care in a genomic age. Personalized Medicine, 2014, 11, 285-295.	1.5	38
9	A Framework for Analyzing the Ethics of Disclosing Genetic Research Findings. Journal of Law, Medicine and Ethics, 2014, 42, 190-207.	0.9	38
10	An ethical framework for genetic counseling in the genomic era. Journal of Genetic Counseling, 2020, 29, 718-727.	1.6	35
11	Towards a more representative morphology: clinical and ethical considerations for including diverse populations in diagnostic genetic atlases. Genetics in Medicine, 2016, 18, 1069-1074.	2.4	27
12	Institutional review board perspectives on obligations to disclose genetic incidental findings to research participants. Genetics in Medicine, 2016, 18, 705-711.	2.4	26
13	Implementing Expanded Prenatal Genetic Testing: Should Parents Have Access to Any and All Fetal Genetic Information?. American Journal of Bioethics, 2021, , 1-26.	0.9	26
14	Views of American OB/GYNs on the ethics of prenatal wholeâ€genome sequencing. Prenatal Diagnosis, 2016, 36, 1250-1256.	2.3	24
15	Noninvasive Prenatal Whole Genome Sequencing. Obstetrics and Gynecology, 2019, 133, 525-532.	2.4	24
16	When Participants in Genomic Research Grow Up: Contact and Consent atÂthe Age of Majority. Journal of Pediatrics, 2016, 168, 226-231.e1.	1.8	17
17	Exploring the motivations of research participants who chose not to learn medically actionable secondary genetic findings about themselves. Genetics in Medicine, 2021, 23, 2281-2288.	2.4	17
18	When Should Genome Researchers Disclose Misattributed Pahentage?. Hastings Center Report, 2015, 45, 28-36.	1.0	14

#	Article	IF	Citations
19	Covid-19 Vaccine Trials and Incarcerated People — The Ethics of Inclusion. New England Journal of Medicine, 2020, 383, 1897-1899.	27.0	14
20	Reconceptualizing harms and benefits in the genomic age. Personalized Medicine, 2018, 15, 419-428.	1.5	13
21	Reconsidering the Need for Reconsent at 18. Pediatrics, 2018, 142, .	2.1	12
22	Finding Fault? Exploring Legal Duties to Return Incidental Findings in Genomic Research. Georgetown Law Journal, 2014, 102, 795-843.	1.0	12
23	Re-examining the Ethics of Genetic Counselling in the Genomic Era. Journal of Bioethical Inquiry, 2020, 17, 325-335.	1.5	11
24	Prenatal Whole Genome Sequencing: An Argument for Professional Self-Regulation. American Journal of Bioethics, 2017, 17, 26-28.	0.9	10
25	Parental Consent for the Use of Residual Newborn Screening Bloodspots. JAMA - Journal of the American Medical Association, 2015, 314, 21.	7.4	9
26	A Proposed Process for Reliably Updating the Common Rule. American Journal of Bioethics, 2017, 17, 8-14.	0.9	6
27	Incorporating explicit ethical reasoning into pandemic influenza policies. The Journal of Contemporary Health Law and Policy, 2009, 26, 1-19.	0.0	6
28	Scrutinizing the Right Not to Know. American Journal of Bioethics, 2015, 15, 17-19.	0.9	5
29	"lt's Just Another Added Benefit― Women's Experiences with Employment-Based Egg Freezing Progr AJOB Empirical Bioethics, 2021, 12, 41-52.	ams. 1.6	5
30	Should germline genome editing be allowed? The effect of treatment characteristics on public acceptability. Human Reproduction, 2021, 36, 465-478.	0.9	5
31	Grappling With Genomic Incidental Findings in the Clinical Realm. Chest, 2014, 145, 226-230.	0.8	4
32	Compensation for egg donation: a zero-sum game. Fertility and Sterility, 2016, 105, 1153-1154.	1.0	4
33	Response to Open Peer Commentaries on "Do Researchers Have an Obligation to Actively Look for Genetic Incidental Findings?― American Journal of Bioethics, 2013, 13, W10-W11.	0.9	3
34	The Ethics of Large-Scale Genomic Research. , 2016, , 53-69.		3
35	Recontacting participants for expanded uses of existing samples and data: a case study. Genetics in Medicine, 2017, 19, 883-889.	2.4	3
36	Development of a consensus approach for return of pathology incidental findings in the Genotype-Tissue Expression (GTEx) project. Journal of Medical Ethics, 2018, 44, 643-645.	1.8	3

#	Article	IF	CITATIONS
37	Commentary on â€~The right not to know and the obligation not to know'. Journal of Medical Ethics, 2020, 46, 304-305.	1.8	3
38	The ethics of encouraging employees to get the COVID-19 vaccination. Journal of Public Health Policy, 2022, 43, 311-319.	2.0	3
39	Allocation of scarce biospecimens for use in research. Journal of Medical Ethics, 2021, 47, 740-743.	1.8	2
40	Navigating Pandemic Moral Distress at Home and at Work: Frontline Workers' Experiences. AJOB Empirical Bioethics, 2022, 13, 215-225.	1.6	2
41	Should institutions fund the feedback of individual findings in genomic research?. Journal of Medical Ethics, 0, , medethics-2021-107992.	1.8	2
42	The Deep Structure of Deliberate Ignorance: Mapping the Terrain., 2021,, 65-88.		1
43	FDA's Proposed Guidance for Laboratory Developed Tests: How Should Regulators Balance the Risks and Promise of Innovation in Clinical Genetics?. FDLI's Food and Drug Policy Forum, 2015, 5, .	0.0	1
44	A new ethical framework to determine acceptable risks in fetal therapy trials. Prenatal Diagnosis, 2022, 42, 962-969.	2.3	1
45	Should Patient Groups Have the Power to Redirect How Their Samples Are Used?. American Journal of Bioethics, 2019, 19, 26-28.	0.9	O
46	Response to Clayton etÂal Genetics in Medicine, 2021, , .	2.4	0
47	Autonomy concerns with using contracts to enhance patient adherence. Bioethics, 2022, , .	1.4	O